Back to Library

Johnson & Johnson

Years Without Answers, Then a Bipolar II Depression Diagnosis

Written by
Johnson & Johnson logoJohnson & Johnson
• Published January 10, 2026 • Updated January 10, 2026 Sponsored Content
Years Without Answers, Then a Bipolar II Depression Diagnosis

Sponsored by Intra-Cellular Therapies.

Jamie didn't know she was living with bipolar II depression for most of her life. For years, she had been misdiagnosed. Her experience is more common than people might think.

Johnson & Johnson creative content

"I started feeling depression symptoms when I was younger. I did feel down a lot. I don't feel I got the support I needed."

—Jamie, living with bipolar II depression

As she got older, Jamie got married, started a family, and ran a crafting business she loved. But her symptoms continued to worsen, she shut down her business and stepped away from crafting for a long time, which saddened her. She was initially diagnosed with major depressive disorder (MDD) and spent more than a decade searching for a treatment that works for her. 

3 in 4 patients with bipolar disorder are misdiagnosed most often with major depressive disorder. 

Antidepressant medications may worsen bipolar symptoms.

Johnson & Johnson creative content

"I honestly felt my depression worsening at times."

—Jamie, living with bipolar II depression

Jamie's Turning Point

Jamie's symptoms became more severe and began to hurt relationships with her family. Finally, she opened up to her healthcare provider. That conversation led to a new diagnosis: bipolar II depression, then her symptoms started to make sense.

Johnson & Johnson creative content

Bipolar I and II disorder affect a similar number of people in the U.S.

''When I started bringing up my worsening symptoms, she diagnosed me with bipolar II depression. It made sense when I looked back at the symptoms I experienced for most of my life.''

—Jamie, living with bipolar II depression

~11 million U.S. adults experience bipolar disorder in their lifetime.

Johnson & Johnson creative content

Bipolar II Depression

  • People tend to experience longer depressive episodes that can be more severe than with bipolar I disorder
  • Having at least one depressive episode and at least one hypomanic episode, without a manic episode

Jamie's story reflects how common a misdiagnosis can be for some people. This can make bipolar II depression hard to identify and treat, especially for those previously diagnosed with depression. 

Opening up to her healthcare provider set Jamie on a path to better understanding her condition.

Johnson & Johnson creative content

Johnson & Johnson creative content

''It's a relief to know what was causing my symptoms for most of my life.''

—Jamie, living with bipolar II depression

Exploring Treatment With CAPLYTA® (lumateperone)

CAPLYTA has Boxed Warnings for increased risk of death in elderly people with dementia-related psychosis and increased risk of suicidal thoughts and behaviors in children and young adults. CAPLYTA is not approved for people under 18. See additional Important Safety Information below.

After her diagnosis, Jamie's healthcare provider introduced CAPLYTA as a treatment option. She liked what she heard: a once-daily pill, no titration required (meaning she didn't need to slowly increase her dose), and in clinical trials, weight gain was not common.

CAPLYTA may cause problems with your metabolism including high blood sugar, diabetes, increased fat (cholesterol and triglyceride) levels in your blood and weight gain. Your healthcare provider should check your blood sugar, fat levels and weight before you start and during your treatment with CAPLYTA.

Please see additional Important Safety Information, including Boxed Warnings, below.

CAPLYTA is proven to provide significant relief from depressive symptoms of bipolar disorder in adults at 6 weeks.


Johnson & Johnson creative content

''I also liked how there was no titration needed. I was on the effective dose from the start.''

—Jamie, living with bipolar II depression

Patient experiences may vary.

After starting treatment, Jamie noticed an improvement in her bipolar depression symptoms.

Johnson & Johnson creative content

She continues to go to therapy regularly and works closely with her healthcare provider. While she still has some challenging days, Jamie reports experiencing improvement in her symptoms and feeling more able to focus on her family and her work.

"Having relief from my bipolar depression allows me to focus on other parts of my life, like my work. I love spending time with my family."

—Jamie, living with bipolar II depression

Patient experiences may vary.

Find more stories of people who are living with bipolar depression.

Learn more about how CAPLYTA can provide symptom relief for bipolar II depression.

The patient in this promotional article is sharing her individual experiences and has been compensated for her time. This promotional resource is brought to you by Intra-Cellular Therapies.


IMPORTANT SAFETY INFORMATION

Medicines like CAPLYTA can raise the risk of death in elderly people who have lost touch with reality (psychosis) due to confusion and memory loss (dementia). CAPLYTA is not approved for treating people with dementia-related psychosis.

CAPLYTA and antidepressant medicines may increase suicidal thoughts and actions in some children, adolescents, and young adults especially within the first few months of treatment or when the dose is changed. Depression and other serious mental illnesses are the most important causes of suicidal thoughts and actions. Patients and their families or caregivers should watch for new or worsening depression symptoms, especially sudden changes in mood, behaviors, thoughts, or feelings. This is very important when CAPLYTA or an antidepressant medicine is started or when the dose is changed. Report any change in these symptoms to your healthcare provider immediately.

Do not take CAPLYTA if you are allergic to any of its ingredients. Get emergency medical help if you are having an allergic reaction (e.g., rash, itching, hives, swelling of the tongue, lip, face, or throat).

CAPLYTA may cause serious side effects, including:

  • Stroke (cerebrovascular problems) in elderly people with dementia-related psychosis that can lead to death.
  • Neuroleptic malignant syndrome (NMS): high fever, confusion, changes in your breathing, heart rate, and blood pressure, stiff muscles, and increased sweating; these may be symptoms of a rare but potentially fatal condition. Contact your healthcare provider or go to the emergency room if you experience signs and symptoms of NMS.
  • Uncontrolled body movements (tardive dyskinesia, TD) in your face, tongue, or other body parts. TD may not go away, even if you stop taking CAPLYTA. It may also occur after you stop taking CAPLYTA.
  • Problems with your metabolism including high blood sugar, diabetes, increased fat (cholesterol and triglyceride) levels in your blood and weight gain. Your healthcare provider should check your blood sugar, fat levels and weight before you start and during your treatment with CAPLYTA. Extremely high blood sugar levels can lead to coma or death. Call your healthcare provider if you have any of the following symptoms of high blood sugar: feeling very thirsty, hungry, sick to your stomach, needing to urinate more than usual, weak/tired, or confused, or your breath smells fruity.
  • Low white blood cell count. Your healthcare provider may do blood tests during the first few months of treatment with CAPLYTA.
  • Decreased blood pressure (orthostatic hypotension). You may feel lightheaded, dizzy, or faint when you rise too quickly from a sitting or lying position.
  • Falls. CAPLYTA may make you sleepy or dizzy, may cause a decrease in your blood pressure when changing position (orthostatic hypotension), and can slow your thinking and motor skills which may lead to falls that can cause broken bones or other injuries.
  • Seizures (convulsions).
  • Sleepiness, drowsiness, feeling tired, difficulty thinking and doing normal activities. Until you know how CAPLYTA affects you, do not drive, operate heavy machinery, or do other dangerous activities.
  • Problems controlling your body temperature so that you feel too warm. Avoid getting overheated or dehydrated while taking CAPLYTA.
  • Difficulty swallowing that can cause food or liquid to get into the lungs.

The most common side effects of CAPLYTA include sleepiness, dizziness, nausea, and dry mouth.

These are not all the possible side effects of CAPLYTA. Tell your healthcare provider if you have or have had heart problems or a stroke, high or low blood pressure, diabetes, or high blood sugar, problems with cholesterol, have or have had seizures (convulsions), kidney or liver problems, or a low white blood cell count. CAPLYTA may cause fertility problems in females and males. You should notify your healthcare provider if you become pregnant or intend to become pregnant while taking CAPLYTA. CAPLYTA may cause abnormal involuntary movements and/or withdrawal symptoms in newborn babies exposed to CAPLYTA during the third trimester. Talk to your healthcare provider if you breastfeed or are planning to breastfeed as CAPLYTA passes into breast milk. Tell your healthcare provider about all the medicines you’re taking. CAPLYTA may affect the way other medicines work, and other medicines may affect how CAPLYTA works, causing possible serious side effects. Do not start or stop any medicines while taking CAPLYTA without talking to your healthcare provider. You are encouraged to report negative side effects of prescription drugs. Contact Intra-Cellular Therapies, Inc. at 1-888-611-4824 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

CAPLYTA is available in 10.5 mg, 21 mg, and 42 mg capsules.

INDICATIONS

CAPLYTA is a prescription medication used in adults for the treatment of depressive episodes associated with bipolar I or bipolar II disorder (bipolar depression). CAPLYTA can be taken alone or with the medicines lithium or valproate for bipolar depression. It is not known if CAPLYTA is safe and effective in children.

Please see Medication Guide, including Boxed Warnings.

© Johnson & Johnson and its affiliates 2025. CAPLYTA is a trademark of Johnson & Johnson and its affiliates. Trademarks listed are the property of their respective owners.

US-CAP-2500121 06/25